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miR-155 is a prominent microRNA (miRNA) that regulates genes involved in immunity and cancer-related pathways.
miR-155 is overexpressed in lung cancer, which correlates with poor patient prognosis. It is unclear how miR-155
becomes increased in lung cancers and how this increase contributes to reduced patient survival. Here, we show that
hypoxic conditions induce miR-155 expression in lung cancer cells and trigger a corresponding decrease in a validated
target, FOXO3A. Furthermore, we find that increased levels of miR-155 radioprotects lung cancer cells, while inhibition of
miR-155 radiosensitizes these cells. Moreover, we reveal a therapeutically important link between miR-155 expression,
hypoxia, and irradiation by demonstrating that anti-miR-155 molecules also sensitize hypoxic lung cancer cells to
irradiation. Our study helps explain how miR-155 becomes elevated in lung cancers, which contain extensive hypoxic
microenvironments, and demonstrates that inhibition of miR-155 may have important therapeutic potential as a means
to radiosensitize hypoxic lung cancer cells.
Introduction
Tumor microenvironments have a prominent role in shaping
malignant progression, and in some cases may be as important as
genetic and epigenetic factors in influencing cancer development.1
Tumor microenvironments, which are often characterized by low
pH, nutrient deprivation, and hypoxia, confer tumor cells with a
marked ability to survive in adverse conditions.2,3 Hypoxia in
particular causes tumors to acquire aggressive characteristics such
as increased metastatic potential,4 decreased drug sensitivity,5
diminished p53-dependent apoptosis,6 and increased genetic
instability and mutation rates.7 Notably, these hypoxia-induced
characteristics have been shown to independently and significantly
correlate with reduced survival in patients with cervical and head
and neck cancers.8,9
Additionally, hypoxia greatly affects tumor responsiveness to
radiation therapy. In normoxic conditions, radiation treatment
generates oxygen radicals that mediate DNA damage and tumor
cell eradication. However, in hypoxic tumor microenvironments,
where intratumoral oxygen is reduced or absent, tumor cells are
2.5–3 times more resistant to radiation therapy, largely due to the
lack of oxygen radical-mediated DNA damage.2,10 Thus, poor
outcome in cancer patients is often a direct result of hypoxia-
induced radioresistance in tumor cells.2,8,9
Interestingly, in the last several years, numerous studies have
identified important links between hypoxia, cancer, and miRNAs.
MiRNAs are negative modulators of gene expression that have
been implicated in almost every mammalian biological process
investigated. A number of miRNAs have been shown to be
regulated by hypoxia and many of them confer cancer cells with
increased ability to adapt to hypoxic conditions and survive. The
most prolific miRNA vis-à-vis hypoxia is miR-210; miR-210 is
upregulated in many cancers and is induced in hypoxic condi-
tions.11 This miRNA has an overall effect of increasing tumor cell
survival by regulating genes involved in DNA repair, angiogenesis,
cell cycle progression, and mitochondrial metabolism.11-13 Addi-
tionally, high miR-210 is associated with poor prognosis in
pancreatic and breast cancer patients,13,14 further implicating it as
a crucial link between hypoxia and cancer outcome. Other
miRNAs regulate or are regulated by hypoxia including miR-
373,15 miR-42416 and miR-17–92.17
Another miRNA, miR-155, has emerged as a “master-
regulator” of numerous biological processes, most notably those
involved in immune function and cancer development. Interest-
ingly, miR-155 is overexpressed in lung cancers18,19 and its
increased expression is associated with poor prognosis in lung
cancer patients.19,20 However, the mechanism for miR-155
upregulation in lung cancer is currently unknown, and it is
*Correspondence to: Joanne B. Weidhaas and Peter M. Glazer and Frank J. Slack; Email: peter.glazer@yale.edu and frank.slack@yale.edu
and joanne.weidhaas@yale.edu
Submitted: 07/13/11; Revised: 08/06/11; Accepted: 08/09/11
http://dx.doi.org/10.4161/cbt.12.10.17681
Cancer Biology & Therapy 12:10, 908–914; November 15, 2011; G 2011 Landes Bioscience
908 Cancer Biology & Therapy Volume 12 Issue 10
©2011 Landes Bioscience.
Do not distribute.
Figure 1. Hypoxia induces miR-155 in lung cancer cells. (A) miR-155 fold-change in A549 cells after the demarcated amounts of time in hypoxia as
measured by qPCR; protein gel blot showing the corresponding changes in FOXO3A protein levels in A549 cells upon exposure to hypoxia. (B) miR-155
fold-change in H460 cells after exposure to 48 h of hypoxia as measured by qPCR; protein gel bot showing the corresponding decrease in FOXO3A
protein expression in H460 cells upon exposure to hypoxia. (C) miR-155 fold-change in A549 cells at the given number of hours after transfer from
hypoxic to normoxic conditions as measured by qPCR; protein gel blot showing the corresponding changes of FOXO3A protein levels in A549 cells after
transfer from hypoxic to normoxic conditions.
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unclear how increased miR-155 levels contribute to poor
prognosis in patients. Here we show that miR-155 is induced
by hypoxia in lung cancer cells. Furthermore, miR-155 radio-
protects lung cancer cells, which may help explain why patients
with increased levels have worse prognosis. Importantly, we find
that inhibition of miR-155 radiosensitizes hypoxic lung cancer
cells, demonstrating a potentially novel therapeutic approach for
lung cancer patients undergoing radiotherapy.
Results
Hypoxia induces miR-155 in lung cancer cells. miR-155 levels
are increased in a number of cancer types, including non-small
cell lung cancer (NSCLC).18,19 Given that miR-155 levels are
increased in lung cancers, which often contain hypoxic tumor
microenvironments,21 we tested whether hypoxia induces
miR-155. Non-small cell lung cancer lines (A549 and H460)
were placed in an incubated cell culture hypoxia chamber for a
time-course of hypoxia (, 0.01% O2) exposure. At various time-
points, cells were removed from hypoxia and immediately
prepared for molecular analysis. We found that miR-155 levels
increased ~2-fold at 8 h of hypoxia exposure and ~8-fold by 48 h
of hypoxia exposure in A549 cells (Fig. 1A). Interestingly, this
corresponded with diminished levels of a validated miR-155
target,22 Forkhead box O3 (FOXO3A), at 24 h hypoxia
exposure and beyond (Fig. 1A). Similarly, H460 cells
demonstrated a ~6-fold induction of miR-155 levels after
48 h of hypoxia exposure and a corresponding decrease
in FOXO3a levels (Fig. 1B).
We next determined a time course for miR-155
downregulation after removal from hypoxic conditions.
miR-155 levels decreased to ~3-fold by 24 h and
approximately 2-fold by 48 h after transfer to normoxic
conditions in A549 cells (Fig. 1C). This corresponded
with a subsequent increase in FOXO3A protein levels by
24 h (Fig. 1C). FOXO3A is a member of the forkhead
family of transcription factors; when unphosphorylated,
FOXO3A localizes to the nucleus where it functions as
a tumor suppressor by inducing genes involved in apo-
ptosis.23 Recently, a study showed that FOXO3A is
negatively regulated by miR-155 in breast cancer cells,
resulting in their reduced chemo-sensitivity.22 Our results
combined with this study support the notion that
hypoxia-induced miR-155 may confer lung cancer cells
with the ability to resist other forms of treatment such
as irradiation, in part by modulating FOXO3A.
HIF-1α is necessary for hypoxic miR-155 induction.
One of the main effectors of hypoxia is the transcription
factor HIF-1α, which is responsible for regulating a wide
variety of cellular pathways including survival and angio-
genesis. Importantly, HIF-1α has been shown to be
necessary for the hypoxia-driven induction of a number
of miRNAs including miR-210 and miR-373.15 To
determine whether HIF-1α is required for the upregula-
tion of miR-155 under hypoxic conditions, we utilized a
stable cell line expressing shRNA to HIF-1α. A549 lung
cancer cells stably expressing either shHIF-1α or a vector control
were exposed to normoxia or hypoxia for 48 h. In the presence
of shHIF-1α, we found that the upregulation of miR-155 is
attenuated in hypoxia (Fig. 2A). These results suggest a role for
HIF-1α in the induction of miR-155 under hypoxic conditions.
Protein gel blot analysis confirmed induction of HIF-1α in
hypoxic conditions and the absence of HIF-1α in hypoxic cells
containing shHIF-1α (Fig. 2B). We found similar results using
MCF7 breast cancer cells (Fig. S1A and B).
miR-155 modulates irradiation response in lung cancer cells.
Several studies have shown that increased miR-155 levels correlate
with poor prognosis in lung cancer patients. In a previous study
(submitted), we found that miR-155 induction in mouse lungs is
not sufficient to initiate tumorigenesis (data not shown). Further-
more, we tested whether miR-155 alters the ability of A549 lung
cancer cells to migrate and/or invade using the Boyden chamber
assay, and in our hands miR-155 did not have an effect (data not
shown).
We then asked whether miR-155 influences the ability of lung
cancer cells to respond to radiotherapy, which could potentially
explain why miR-155 contributes to poor prognosis in lung
cancer patients. We found that miR-155 is expressed and induced
by hypoxia in the two NSCLC cell lines A549 and H460 (Fig. 1A
and B). We then transfected A549 and H460 cancer cells with
Figure 2. Knockdown of HIF-1α attenuates induction of miR-155 in response to
hypoxia in A549 cells. (A) miR-155 fold-change as measured by qPCR in A549 lung
cancer cells expressing a vector control or an shRNA to HIF-1α. Cells were exposed
to normoxia or hypoxia for 48 h and miR-155 levels were monitored. After hypoxia,
miR-155 is induced ~4-fold in control cells, while only a ~2-fold induction of miR-
155 is observed in cells expressing shRNA to HIF-1α. (B) Protein gel blot confirms
HIF-1α knockdown.
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synthetic pre-miR-155 molecules or pre-control molecules con-
taining a scrambled sequence (Ambion). Sixteen hours post-
transfection, cells were treated with varying doses of irradiation
and plated for a clonogenic assay, which measures all forms of
irradiation-induced cell death. We found that increased levels
of miR-155 had a radio-protective effect on A549 cells (Fig. 3A;
p = 0.0002) and H460 cells (Fig. 3B; p = 0.0013) compared with
control molecules. We also tested whether inhibition of miR-155
affects radioresistance of these lung cancer cells. Anti-miR-155 or
anti-control molecules were transfected into A549 or H460 cells.
As before, cells were treated with varying doses of irradiation at
16 h post-transfection and plated for a clonogenic assay. In con-
cordance with our previous results, we found that inhibition of
miR-155 significantly sensitized both A549 cells (Fig. 3C; p =
0.000029) and H460 cells (Fig. 3D; p = 0.002) to radiation treat-
ment. These results suggest that miR-155 alone can significantly
impact the ability of lung cancer cells to respond to irradiation.
Inhibition of miR-155 radiosensitizes hypoxic lung cancer
cells. Given that tumor microenvironments are characterized by
hypoxia and that hypoxia confers radioresistant properties to
cancer cells, we tested the therapeutic effect of miR-155 inhibi-
tion combined with irradiation in hypoxic lung cancer cells. A549
and H460 cells were transfected with synthetic anti-miR-155
molecules and anti-control molecules. After 4 h, cells were trans-
ferred to mobile irradiation-permissive hypoxia chambers and
incubated for 16 h. The cells were then treated with varying doses
of irradiation while being maintained in hypoxic conditions.
We found that incubation of cells in the mobile irradiation-
permissive hypoxia chambers was sufficient to induce hypoxia-
inducible factor 1 α (HIF-1α) (Fig. 4A), confirming the effective
establishment of hypoxia. After irradiation, cells were plated for
a clonogenic assay based on colony formation in normoxic
conditions as described previously. We found that inhibition of
miR-155 significantly radiosensitized hypoxic A549 cells
(Fig. 4B; p = 0.00008) and hypoxic H460 cells (Fig. 4C;
p = 0.018). Since hypoxic tumor microenvironments substanti-
ally influence radiotherapy in lung cancer patients, these results
support miR-155 inhibition as a therapeutically promising
approach when combined with radiotherapy.
Discussion
As tumor cells rapidly proliferate, they outgrow their blood supply
and thus forfeit their normal access to oxygen; this creates an
Figure 3. miR-155 modulates irradiation response in lung cancer cells. (A) Survival curve comparing pre-miR-155 or pre-control treated A549 cells upon
exposure to the given doses of irradiation. (B) Survival curve comparing pre-miR-155 or pre-control treated H460 cells upon exposure to the given doses
of irradiation. (C) Survival curve comparing anti-miR-155 or anti-control treated A549 cells upon exposure to the given doses of irradiation. (D) Survival
curve comparing anti-miR-155 or anti-control treated H460 cells upon exposure to the given doses of irradiation.
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hypoxic tumor microenvironment. It is well established that
hypoxia substantially affects tumor cells ability to respond to
irradiation. Given that radiotherapy is one of the primary
modalities of cancer treatment and that more than 50% of
lung cancer patients eventually receive irradiation,24 this contri-
butes to the poor overall survival of lung cancer patients, and
lung cancer remains the leading cause of cancer deaths worldwide.
miR-155 has emerged as an important miRNA involved in
lung cancer as its increased expression is significantly correlated
with poor prognosis.19,20 Here we present one means by which
miR-155 is upregulated in lung cancer cells, namely hypoxia.
More specifically, we identify a role for HIF-1α in the induction
of miR-155. Our data are further supported by the observation
that miR-155 is induced in renal cancer cells lacking functional
Von Hippel-Lindau (VHL), and that this induction depends
in part on HIF-1α expression.25 Intriguingly, the connection
between miR-155 and hypoxia is further supported by the
observation that both hypoxia and increased miR-155 are
associated with increased mutation rates in cancer cells7,26 and
deregulation of DNA repair pathways such as mismatch repair
(MMR).27,28 These results suggest that hypoxia-induced geno-
mic instability may in part be mediated via miR-155 induction.
Furthermore, the link between increased miR-155 and reduced
survival in lung cancer patients may be partially explained by
miR-155-mediated radioresistance, which reduces the effective-
ness of radiotherapy. Although miR-155 regulates numerous
genes in several pathways, its regulation of cellular senescence
and apoptosis via targeting of genes such as FOXO3A and
tumor protein 53-induced nuclear protein 1 (TP53INP1) in
particular is likely to account for its radio-protective effects in
lung cancer cells.22,29,30 As miR-155 continues to emerge as a
master gene regulator that promotes tumor cell survival,
therapies focused on its inhibition will likely prove to be
advantageous for cancer patients.
Materials and Methods
Cells. A549 cells were cultured in F12 media supplemented
with 10% fetal bovine serum (FBS); H460 cells were cultured in
RPMI media + 10% FBS. Cells were maintained in an incubator
at 37 degrees with 5% CO2 according to standard procedures.
A549, H460, and MCF7 cells were obtained from ATCC, which
authenticates cells using short tandem repeat (STR) profiling,
morphological analysis, karyotyping, and isoenzyme analysis.
Clonogenic assays. Clonogenic assays were performed accord-
ing to standard protocols.31 Briefly, cells were reverse trans-
fected with 50 nM of anti- or pre-RNAs using siPORT NeoFX
(Ambion). After 16 h cells were treated with increasing doses of
irradiation using an X-RAD 320 Biological Irradiator, plated at
different dilutions, and incubated for 2 weeks. Two dilutions
were used for every treatment group and each dilution was
plated in quadruplicate. Cells were stained with crystal violet
(0.5% w/v) in 80% methanol, clonogens were blindly counted,
and results were compiled and normalized to the no irradiation
treatment groups. Statistical analysis was performed using
stratified t-tests based on a two-tailed evaluation of data.
Hypoxia. Cells were incubated at 37 degrees in hypoxic
chambers infiltrated with 95% nitrogen, 5% carbon dioxide,
, 0.01% oxygen for the indicated amounts of time.
Figure 4. Inhibition of miR-155 radiosensitizes hypoxic lung cancer cells.
(A) Protein gel blot showing HIF-1α induction in cells incubated in mobile
irradiation-permissive hypoxia chambers. (B) Survival curve showing anti-
miR-155 treatment compared with anti-control treatment in hypoxic A549
cells at the given doses of irradiation. (C) Survival curve showing anti-miR-
155 treatment compared with anti-control treatment in hypoxic H460 cells
at the given doses of irradiation.
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qPCR. RNA was extracted using the mirVana miRNA
Isolation kit (Applied Biosystems). cDNA was synthesized from
total RNA using the Taqman miRNA High-Capactiy cDNA
Reverse Transcription kit (Applied Biosystems) with primers
specific to miR-155 or RNU6B, an endogenous control. Quanti-
tative PCR was performed according to the manufacturer’s
protocol using the Taqman microRNA PCR system (Applied
Biosystems) as previously described.15 Briefly, cDNA was com-
bined with Taqman Universal PCR Master Mix and probes
specific for miR-155 or RNU6B (Applied Biosystems). PCR was
performed in 96-well optical plates. miRNA Ct values were
normalized to RNU6B Ct values and relative expression was
calculated using the -ΔΔCt method.
Protein gel blot. Cells were removed from normoxia or
hypoxia conditions and immediately placed on ice. After rinsing
with phosphate buffered solution (PBS) cells were scraped,
collected, and used for protein extraction with AZ lysis buffer.
50 μg total protein was loaded and size fractionated via SDS/
PAGE and transferred to a PVDF membrane. Antibodies were
as follows: mouse monoclonal anti-HIF-1α (BD Transduction
Laboratories; Cat: 610958); mouse monoclonal anti-α-tubulin
(B-5–1-2; Sigma-Aldrich); rabbit polyclonal anti-FOXO3a
[Abcam; ab55010; mouse monoclonal anti-b-actin (Santa Cruz;
sc-47778)].
Inhibition of HIF-1α by shRNA. Short hairpin RNA (shRNA)
to HIF-1α (shHIF-1α) was expressed in A549 or MCF7 cells as
previously described.15 Briefly, lentiviral infection was used to
introduce a control vector or an shHIF-1α in A549 or MCF7
cells. Cells expressing the vectors were identified by GFP and
collected for further experiments. A549 or MCF7 cells expressing
shHIF-1α or a control were exposed to 48 h of normoxia or
hypoxia. RNA and protein were isolated for qPCR and protein gel
blot, respectively.
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